尼弗拉泰尔通过调节GADD45A诱导三阴性乳腺癌细胞G2/M阶段阻断和亡
Yuhang Hou1, Hongyun Hao1, Yan Yuan1
1New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing 210000, China.
Pharmaceuticals (Basel, Switzerland)
|October 26, 2024
概括
尼富拉特 (NF113) 通过抑制增殖和诱导亡,显示出对三阴性乳腺癌的抗瘤作用. 这通过GADD45A的上调发生,影响关键细胞周期和信号通路.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼弗拉泰尔 (NF113) 是一种酸衍生物,具有抗瘤的特性.
- 在三阴性乳腺癌 (TNBC) 中NF113的精确机制尚未完全理解.
- 瘤瘤仍然是一个具有挑战性的亚型,目标治疗有限.
研究的目的:
- 为了研究nifuratel (NF113) 在三阴性乳腺癌中的抗瘤机制.
- 在TNBC的体外和体外模型中评估NF113的疗效.
- 为了阐明NF113在乳腺癌中准的分子途径.
主要方法:
- 使用CCK8和殖民地形成试验来评估细胞增殖.
- 通过流式细胞计量分析了亡和细胞周期分布.
- 转录组测序,PCR,西斑和异种/有机体模型被用于验证机制.
主要成果:
- 在体外和体内,NF113对TNBC表现出显著的抗瘤活性.
- 在TNBC细胞中,NF113治疗导致了亡和G2/M阶段停止的增加.
- NF113降低了GADD45A的表达,影响了下游的CDC25C和AKT酸化.
结论:
- 尼弗拉泰尔 (NF113) 通过上调调节GADD45A.通过抑制三阴性乳腺癌的生长.
- 通过GADD45A/CyclinB/CDK1通路,NF113可能会诱导G2/M阶段停止.
- 通过GADD45A/JNK/P38途径可能发生NF113诱导的亡.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:17The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K